Open AccessMacrocycle Therapeutics to Treat Life-threatening Diseases
Author(s) -
Gokhan Batur,
Philipp Ermert,
Johann Zimmermann,
Daniel Obrecht
Publication year - 2021
Publication title -
chimia
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.387
H-Index - 55
eISSN - 2673-2424
pISSN - 0009-4293
DOI - 10.2533/chimia.2021.508
Subject(s) - eribulin , medicine , antibiotics , elastase , cancer research , pharmacology , breast cancer , metastatic breast cancer , cancer , chemistry , microbiology and biotechnology , biology , biochemistry , enzyme
Polyphor's macrocycle platform led to the discovery of novel antibiotics addressing specifically Gramnegative bacteria by targeting outer membrane proteins. Furthermore, POL6014, an inhibitor of neutrophile elastase and balixafortide, a CXCR4 inhibitor have been discovered and developed from the platform. Currently a combination of balixafortide and eribulin is in Phase III clinical trial for the treatment of patients with advanced metastatic HER2-negative breast cancer.